SAVA - Why Cassava Sciences Stock Surged Today | Benzinga
Cassava Sciences, Inc. (NASDAQ: SAVA) shares are trading higher after the company announced MRI data suggested simufilam is not associated with amyloid-related imaging abnormalities.
What To Know: The data, from Alzheimer's patients who are enrolled in a Phase 3 clinical trial of simufilam, suggests that the drug is not associated ...